AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16003508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for axillary recess
Number of subjects: 26
Study 16003508 — intervention group
Group type: EXPERIMENTAL
Intervention: Interobserver reliability for rotator interval
Number of subjects: 26
Study 12558609 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic salbutamol inhaled three times during a 6-h period
Number of subjects: 15
Study 12558609 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (control)
Number of subjects: 15
Study 10053176 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 to 40 mg per day) with possible addition of enalapril (5 to 20 mg per day) or hydrochlorothiazide (12.5 to 25 mg per day) or both, titrated to reduce systolic blood pressure by at least 20 mm Hg and to less than 150 mm Hg.
Number of subjects: 4695
Study 8909665 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD+IAT
Number of subjects: 57
Study 8909665 — intervention group
Group type: EXPERIMENTAL
Intervention: PHD+IAT+HA
Number of subjects: 57
Study 8909665 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 57
Study 1681343 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum (ultrasonic nebuliser)
Number of subjects: 67
Study 1681343 — intervention group
Group type: COMPARATOR
Intervention: Ordinary sputum (expectoration)
Number of subjects: 67
Study 1681343 — intervention group
Group type: COMPARATOR
Intervention: Bronchoscopy
Number of subjects: 67
Study 6347014 — intervention group
Group type: EXPERIMENTAL
Intervention: Op-Site sutureless skin closures
Number of subjects: 55
Study 6347014 — intervention group
Group type: COMPARATOR
Intervention: Continuous nylon sutures
Number of subjects: 55
Study 30952386 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intra‐ and postoperative tranexamic acid (TXA) treatment
Number of subjects: 30
Study 29394003 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch with replacement PIB adhesive (test)
Number of subjects: 0
Study 29394003 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch with previously used PIB adhesive (reference)
Number of subjects: 0
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) implantation
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) in Fontan circulation with systolic dysfunction
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) in Fontan circulation with systolic dysfunction
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) in Fontan circulation with diastolic dysfunction
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) in Fontan circulation with diastolic dysfunction
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Ventricular Assist Device (RVAD) with pulmonary vascular resistance increment
Number of subjects: 30
Study 26494529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular Assist Device (VAD) speed adjustment
Number of subjects: 30
Study 24256372 — intervention group
Group type: EXPERIMENTAL
Intervention: HMG
Number of subjects: 90
Study 24256372 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (C)
Number of subjects: 90
Study 24256372 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate + HMG (CH)
Number of subjects: 90
Study 22131101 — intervention group
Group type: EXPERIMENTAL
Intervention: Paquinimod (4.5 mg/day and 6.0 mg/day)
Number of subjects: 0
Study 22131101 — intervention group
Group type: EXPERIMENTAL
Intervention: Paquinimod (up to 3.0 mg/day)
Number of subjects: 0
Study 22131101 — intervention group
Group type: EXPERIMENTAL
Intervention: Paquinimod
Number of subjects: 0
Study 22131101 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone and mycophenolate mofetil
Number of subjects: 0
Study 21055907 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate release alprazolam, extended release alprazolam, clonazepam
Number of subjects: 6
Study 17414726 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based online training course
Number of subjects: 50
Study 15680718 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0
Study 15680718 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevalent anemia at randomization
Number of subjects: 0
Study 15680718 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident anemia after randomization
Number of subjects: 0
Study 12067168 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined antibiotics (neomycin and metronidazole orally)
Number of subjects: 215
Study 12067168 — intervention group
Group type: COMPARATOR
Intervention: Systemic antibiotics (placebo)
Number of subjects: 215
Study 10508004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg moxifloxacin
Number of subjects: 12
Study 10508004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous infusion of 400 mg moxifloxacin over 60 min
Number of subjects: 12
Study 10508004 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of 400 mg moxifloxacin
Number of subjects: 12
Study 7861488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dornier HM3 lithotriptor
Number of subjects: 13864
Study 7861488 — intervention group
Group type: COMPARATOR
Intervention: Medstone STS lithotriptor
Number of subjects: 13864
Study 2116622 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate coronary angioplasty following successful thrombolysis
Number of subjects: 0
Study 2116622 — intervention group
Group type: COMPARATOR
Intervention: Delayed elective angioplasty
Number of subjects: 0
Study 7031582 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 258
Study 7031582 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 258
Study 31981412 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized meal (3,600 kJ)
Number of subjects: 10
Study 31981412 — intervention group
Group type: COMPARATOR
Intervention: Fasting
Number of subjects: 10
Study 31272285 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfection of miR‐145‐5p inhibitor
Number of subjects: 0
Study 31272285 — intervention group
Group type: COMPARATOR
Intervention: High glucose group
Number of subjects: 0
Study 31272285 — intervention group
Group type: EXPERIMENTAL
Intervention: FGF5 knockdown
Number of subjects: 0
Study 28846584 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectation manipulation intervention
Number of subjects: 124
Study 28846584 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive therapy
Number of subjects: 124
Study 28846584 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (SMC)
Number of subjects: 124
Study 28846584 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative interventions (Expectation manipulation and Supportive therapy)
Number of subjects: 124
Study 26782835 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense hypertension treatment
Number of subjects: 0
Study 26782835 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 0
Study 26782835 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 24421302 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO) 25 mg and Pioglitazone (PIO) 30 mg daily
Number of subjects: 71
Study 24421302 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin (ALO) 25 mg daily monotherapy
Number of subjects: 71
Study 24421302 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 71
Study 22782482 — intervention group
Group type: COMPARATOR
Intervention: 10 Hz TMS stimulation (study 1)
Number of subjects: 64
Study 22782482 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz TMS stimulation (study 1)
Number of subjects: 64
Study 22782482 — intervention group
Group type: COMPARATOR
Intervention: 1 Hz TMS stimulation (study 2)
Number of subjects: 64
Study 22782482 — intervention group
Group type: COMPARATOR
Intervention: 5 Hz TMS stimulation (study 2)
Number of subjects: 64
Study 22782482 — intervention group
Group type: COMPARATOR
Intervention: 10 Hz TMS stimulation (study 2)
Number of subjects: 64
Study 18727140 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal caregiving time assessment using a German adaptation of the Resource Utilization in Dementia (RUD) questionnaire
Number of subjects: 0
Study 18727140 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclusion of time from all informal caregivers
Number of subjects: 0
Study 18727140 — intervention group
Group type: EXPERIMENTAL
Intervention: Interviewing the primary informal caregiver
Number of subjects: 0
Study 17156824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose HT (1 mg 17 beta‐estradiol + 0.5 mg norethisterone acetate)
Number of subjects: 202
Study 17156824 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dose HT (2 mg 17 beta‐estradiol + 1 mg NETA)
Number of subjects: 202
Study 17156824 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg)
Number of subjects: 202
Study 17156824 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg)
Number of subjects: 202
Study 15151621 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 21
Study 15151621 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 21
Study 12484051 — intervention group
Group type: EXPERIMENTAL
Intervention: PHAI (5-FU: 500 mg/body/week for 50 cycles) plus oral UFT-E (400 mg/body/day for 24 months)
Number of subjects: 49
Study 12484051 — intervention group
Group type: COMPARATOR
Intervention: UFT-E alone
Number of subjects: 49
Study 12484051 — intervention group
Group type: EXPERIMENTAL
Intervention: PHAI
Number of subjects: 49
Study 9849245 — intervention group
Group type: EXPERIMENTAL
Intervention: Arglaes film dressing (a transparent dressing containing silver ions)
Number of subjects: 31
Study 9849245 — intervention group
Group type: COMPARATOR
Intervention: Tegaderm (a transparent polyurethane dressing)
Number of subjects: 31
Study 7926076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (60 mg)
Number of subjects: 62
Study 7926076 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone (40 mg)
Number of subjects: 62
Study 7926076 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 2684174 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms of muroctasin for 6 days post-chemotherapy
Number of subjects: 0
Study 2684174 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of muroctasin for 6 days post-chemotherapy
Number of subjects: 0
Study 786689 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg/day)
Number of subjects: 28
Study 786689 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (1600 mg/day)
Number of subjects: 28
Study 786689 — intervention group
Group type: COMPARATOR
Intervention: Chlorthalidone (100 mg 3 times weekly)
Number of subjects: 28
Study 31157556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (three lozenges per day for two weeks)
Number of subjects: 64
Study 31157556 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges (three lozenges per day for two weeks)
Number of subjects: 64
Study 31157556 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges
Number of subjects: 64
Study 31157556 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 64
Study 28578646 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5%
Number of subjects: 0
Study 28578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 100 mcg clonidine
Number of subjects: 0
Study 28578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 4 mg dexamethasone and 100 mcg clonidine
Number of subjects: 0
Study 28578646 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with 4 mg dexamethasone
Number of subjects: 0
Study 26072017 — intervention group
Group type: EXPERIMENTAL
Intervention: M72/AS01E vaccine
Number of subjects: 0
Study 26072017 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23477886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated seeds
Number of subjects: 40
Study 23477886 — intervention group
Group type: COMPARATOR
Intervention: Regular seeds
Number of subjects: 40
Study 21900439 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary compensation ($150)
Number of subjects: 211
Study 21900439 — intervention group
Group type: COMPARATOR
Intervention: Continuing medical education (CME) credits (5 hours)
Number of subjects: 211
Study 21900439 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participation (all physicians approached)
Number of subjects: 211
Study 19563186 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral administration of Flunarizine Hydrochloride vacuity capsules, thrice each week for 4 weeks.
Number of subjects: 60
Study 19563186 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Flunarizine Hydrochloride capsules combined with acupuncture at placebo-points, thrice each week for 4 weeks.
Number of subjects: 60
Study 16889569 — intervention group
Group type: EXPERIMENTAL
Intervention: TCC locked with cefotaxime (10 mg/mL) and heparin (5000 U/mL)
Number of subjects: 113
Study 16889569 — intervention group
Group type: COMPARATOR
Intervention: TCC with heparin (5000 U/mL) alone
Number of subjects: 113
Study 15351163 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (stenting plus abciximab)
Number of subjects: 401
Study 15351163 — intervention group
Group type: COMPARATOR
Intervention: Control (stenting without abciximab)
Number of subjects: 401
Study 11137279 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 h/week day hospital program (DH12)
Number of subjects: 94
Study 11137279 — intervention group
Group type: COMPARATOR
Intervention: 6 h/week outpatient program (OP6)
Number of subjects: 94
Study 9425400 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH infusion
Number of subjects: 26
Study 9425400 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-2 infusion
Number of subjects: 26
Study 9425400 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH + GHRP-2 infusion
Number of subjects: 26
Study 9425400 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 26
Study 8505663 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (600 mg single dose)
Number of subjects: 53
Study 8505663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3685573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT)
Number of subjects: 59
Study 3685573 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline (OT)
Number of subjects: 59
Study 3685573 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 59
Study 3685573 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT) and Oxaprotiline (OT)
Number of subjects: 59
Study 29669536 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver-inclusive assistive technology intervention
Number of subjects: 90
Study 29669536 — intervention group
Group type: COMPARATOR
Intervention: Customary care
Number of subjects: 90
Study 26603017 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous dual-task training
Number of subjects: 58
Study 26603017 — intervention group
Group type: EXPERIMENTAL
Intervention: Homogeneous dual-task training
Number of subjects: 58
Study 26603017 — intervention group
Group type: COMPARATOR
Intervention: Active placebo (computer lessons)
Number of subjects: 58
Study 25588130 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-soluble vitamins
Number of subjects: 60
Study 25588130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23392532 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gamble (high probability of winning)
Number of subjects: 0
Study 23392532 — intervention group
Group type: COMPARATOR
Intervention: Low-risk control gamble
Number of subjects: 0
Study 23392532 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental gamble (actual outcome presented)
Number of subjects: 0
Study 23392532 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticipation of reward
Number of subjects: 0
Study 21393376 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio Diaries program
Number of subjects: 300
Study 21393376 — intervention group
Group type: COMPARATOR
Intervention: Radio Diaries program followed by group discussion
Number of subjects: 300
Study 18462303 — intervention group
Group type: EXPERIMENTAL
Intervention: Compeed cold sore patch (CSP)
Number of subjects: 351
Study 18462303 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir cream 5%
Number of subjects: 351
Study 17100814 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape
Number of subjects: 60
Study 17100814 — intervention group
Group type: COMPARATOR
Intervention: Pubovaginal sling
Number of subjects: 60
Study 17100814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 14979215 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11234463 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg)
Number of subjects: 157
Study 11234463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 9252517 — intervention group
Group type: EXPERIMENTAL
Intervention: loxiglumide (CCK-A antagonist)
Number of subjects: 12
Study 9252517 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 12
Study 1492262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam (1.0 g/0.5 g) with probenecid (1 g)
Number of subjects: 274
Study 1492262 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (0.25 g)
Number of subjects: 274
Study 1492262 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam with probenecid
Number of subjects: 274
Study 1492262 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 274
Study 3986258 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral nondominant ECT
Number of subjects: 58
Study 3986258 — intervention group
Group type: COMPARATOR
Intervention: Bilateral ECT
Number of subjects: 58
Study 30871496 — intervention group
Group type: EXPERIMENTAL
Intervention: DHAPP + SLDPQ
Number of subjects: 109
Study 30871496 — intervention group
Group type: COMPARATOR
Intervention: DHAPP alone
Number of subjects: 109
Study 29380728 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (1.5 mg twice daily)
Number of subjects: 194
Study 29380728 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus (control group)
Number of subjects: 194
Study 27550305 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lifestyle modification (supervised intervention by two dietitians over 6 months)
Number of subjects: 130
Study 27550305 — intervention group
Group type: COMPARATOR
Intervention: Passive lifestyle modification (leaflet guidance only over 6 months)
Number of subjects: 130
Study 27550305 — intervention group
Group type: EXPERIMENTAL
Intervention: Active lifestyle modification
Number of subjects: 130
Study 27550305 — intervention group
Group type: COMPARATOR
Intervention: Passive lifestyle modification
Number of subjects: 130
Study 24632146 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior metal-free polymer crowns with glass-fibre framework (group 1)
Number of subjects: 120
Study 24632146 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior metal-free polymer crowns without framework (group 2)
Number of subjects: 120
Study 24632146 — intervention group
Group type: COMPARATOR
Intervention: Metal-ceramic crowns (control group)
Number of subjects: 120
Study 22699194 — intervention group
Group type: EXPERIMENTAL
Intervention: Stochastic resonance whole-body vibration training
Number of subjects: 38
Study 22699194 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 38
Study 20953593 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 μg (4.86 μmol)
Number of subjects: 360
Study 20953593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 17114888 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance test (OGTT) in patients with active acromegaly (AA)
Number of subjects: 41
Study 17114888 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (OGTT) in group A controls
Number of subjects: 41
Study 17114888 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (ITT) in patients with growth hormone deficiency (GHD)
Number of subjects: 41
Study 17114888 — intervention group
Group type: COMPARATOR
Intervention: Insulin tolerance test (ITT) in group B controls
Number of subjects: 41
Study 16258579 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback training
Number of subjects: 40
Study 16258579 — intervention group
Group type: COMPARATOR
Intervention: Classical exercise program
Number of subjects: 40
Study 12412171 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen (Arm Y: every 4 weeks; Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Number of subjects: 162
Study 12412171 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen (Arm Z: every 3 weeks) consisting of epirubicin (240 mg/m(2)), bleomycin (60 mg/m(2)), vinblastine (20 mg/m(2)), vincristine (4 mg/m(2)), cyclophosphamide (4000 mg/m(2)), etoposide (900 mg/m(2)), methotrexate (180 mg/m(2)), methylprednisolone (1500 mg/m(2)) over 12 weeks followed by extended-field lymph node irradiation (involved areas, 40 grays [Gy]; noninvolved areas, 30 Gy).
Number of subjects: 162
Study 10807190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination tablet regimen (lamivudine 150 mg/zidovudine 300 mg twice daily plus a protease inhibitor)
Number of subjects: 223